"10.1371_journal.pone.0055807","plos one","2013-02-04T00:00:00Z","Jun Hata; Hisatomi Arima; Sophia Zoungas; Greg Fulcher; Carol Pollock; Mark Adams; John Watson; Rohina Joshi; Andre Pascal Kengne; Toshiharu Ninomiya; Craig Anderson; Mark Woodward; Anushka Patel; Giuseppe Mancia; Neil Poulter; Stephen MacMahon; John Chalmers; Bruce Neal; on behalf of the ADVANCE Collaborative Group","The George Institute for Global Health, University of Sydney, Sydney, New South Wales, Australia; School of Public Health, Monash University, Clayton, Victoria, Australia; Royal North Shore Hospital, Sydney, New South Wales, Australia; Royal Prince Alfred Hospital, Sydney, New South Wales, Australia; Sydney Adventist Hospital Clinical School, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia; University of Milan-Bicocca, Milan, Italy; Imperial College, London, United Kingdom","Revised the manuscript critically for important intellectual content: HA SZ GF CP MA JW RJ APK TN CA MW AP GM NP SM JC BN. Conceived and designed the experiments: JH HA SZ GF CP MA JW RJ APK TN CA MW AP GM NP SM JC BN. Analyzed the data: JH. Wrote the paper: JH HA JC BN.","The authors have read the journals policy and have the following conflicts: SZ reports being an advisory board member for MSD, Novo Nordisk, Sanofi Aventis, Boehringer Ingelheim, Astra Zeneca, and BMS, and receiving lecture fees from Servier, MSD, Novartis, Novo Nordisk, Boheringer Ingelheim, Sanofi Aventis, Astra Zeneca and BMS. CP reports being an advisory board member for Amgen, Boehringer Ingelheim, MSD, Janssen Cilag, Reata and Abbott, and receiving lecture fees from MSD, Boehringer Ingelheim and BMS. MW reports receiving consulting fees from Roche and lecture fees from Servier and Sonofi Aventis. NP reports receiving grant support from Pfizer, Julius Clinical Research, and Novartis, and lecture fees from Gilead, Daiichi-Sankyo, Servier, Takeda, Pfizer, Novo-Nordisk, Roche, Boehringer Ingelheim, Medtronic, and Jannsen. SM reports being an advisory board member for Servier, Pfizer, and Novartis, and receiving lecture fees from Servier and Pfizer and grant support from Servier, Pfizer, and Novartis. JC reports being a member of an advisory board for Servier and receiving lecture fees and grant support from Servier. BN reports being a board member of Roche, Takeda, and Pepsico and receiving lecture fees from Amgen, AstraZeneca, GlaxoSmithKline, Novartis, Pepsico, Pfizer, Pharmacy Guild of Australia, Sanofi Aventis, Servier, and Tanabe. This study was partly funded by Servier. There are no patents, products in development, or marketed products products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","02","Jun Hata","JH",19,TRUE,18,NA,1,4,TRUE,TRUE,FALSE,0,NA,FALSE
